
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1563894
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lymphopenic condition after radiotherapy or chemotherapy could create an environment to induce an efficient antitumor immunity through the homeostatic proliferation of residual or adoptive lymphocytes. However, the antitumor immunity decreased rapidly with tumor growth, and the mechanism remained elusive. The aim of this study is to investigate the role of PD-1 signaling upon homeostatic proliferation-induced antitumor immunity in malignant melanoma. In this study, we found that although T cells proliferated continuously in lymphopenic mice, the number of IFN-γ-releasing CD8 + T cells rapidly decreased in course of homeostatic proliferation. The expression of PD-1 on T cells, increased gradually in course of homeostatic proliferation, were significantly negatively related to the cytotoxicity of effector T cells. Blocking of PD-1/PD-L1 axis by PD-1 antibody promoted homeostasis proliferating(HP) T cells to recognize tumor associated antigen (TAA) and resulted in the activation of DC cells. It can also enhanced the number of IFN-γ -releasing CD8 + T cells and the cytotoxicity of effector T cells and induced a portion of tumor-specific effector T cells convert to central memory T cells. These findings suggested that the PD-1/PD-L1 axis plays a crucial role in immune tolerance formation during homeostatic proliferation. Anti-PD-1 therapies might be used to enhance antitumor immunity during recovery from lymphopenia after chemotherapy or radiotherapy.
Keywords: PD-1/PD-L1, Lymphopenic condition, Immunotherapy, Melanoma, Homeostatic proliferation Tumor draining lymph nodes Tumor-NDLNs: Tumor-non draining lymph nodes Tregs : Regulatory T Cells MDSCs: Myeloid-derived suppressor cells
Received: 20 Jan 2025; Accepted: 07 Apr 2025.
Copyright: © 2025 Yang, Zhu, Wang, Lin and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zike Yang, Zhongshan Hospital, Xiamen University, Xiamen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.